[Peoria, Illinois] – April 28th, 2025 – Veloxity Labs, a leading bioanalytical contract research organization (CRO) specializing in LC-MS bioanalysis, today announced a strong start to 2026, marked by continued double-digit growth, expanded client partnerships and ongoing investment in laboratory capacity and talent.
The company reported growth across its core service areas, supporting an increasing number of discovery, preclinical and clinical-stage programs for pharmaceutical, biotechnology and animal health sponsors.
“This has been a very strong start to the year,” said Shane Needham, President and CEO of Veloxity Labs. “We continue to see growing demand from sponsors who need high-quality bioanalytical data delivered quickly to support critical development decisions.”
To support this growth while maintaining its operational model, Veloxity recently added an additional SCIEX 6500+ mass spectrometry system and expects to bring two more mass spectrometers online in the coming months. These additions build on the company’s fourth quarter 2025 expansion, which included the integration of a SCIEX ZenoTOF 8600 high-resolution accurate mass (HRAM) system to support complex and peptide-based bioanalysis.
Veloxity also expanded its scientific team in the first quarter, adding two scientists and an additional PhD-level scientist to support increasing study volume and client demand.
The company’s turnaround times remain unchanged and continue to be among the fastest in the industry, reflecting Veloxity’s 80% capacity operating model and its focus on quality from inception.
“Our ability to scale while maintaining speed and quality is intentional,” added Needham. “Operating at 80% capacity and continuing to innovate across our workflows allows us to grow without introducing delays or compromising data integrity.”
In addition to its operational growth, Veloxity continues to contribute to industry discussions on bioanalytical strategy and drug development timelines, including recent thought leadership focused on accelerating bioanalysis across the drug development lifecycle and supporting emerging therapeutic areas such as peptides and GLP-1 receptor agonists.
The company remains founder-funded and operated, a model it believes has enabled disciplined growth while maintaining focus on client outcomes and scientific excellence.
As Veloxity moves through 2026, the company expects continued expansion across its client base and analytical capabilities, with a focus on supporting increasingly complex bioanalytical programs while maintaining rapid turnaround times.
“The future is bright,” said Needham. “We’re continuing to surpass our growth targets and remain committed to helping our clients move at the speed of bioanalysis.”
About Veloxity Labs
Veloxity Labs is a bioanalytical contract research organization (CRO) focused on accelerating drug development through high-quality LC-MS bioanalysis and rapid data turnaround. The company supports pharmaceutical, biotechnology and animal health sponsors across discovery, preclinical and clinical programs, providing regulated (GLP/GCP) and non-regulated bioanalytical services.
Founded to address industry timeline challenges, Veloxity operates with an 80% capacity model that enables fast study initiation and consistently short turnaround times while maintaining strict quality and compliance standards. The laboratory offers integrated bioanalysis and PK/TK analysis, supporting efficient decision-making across the drug development lifecycle.
Veloxity’s capabilities span small molecules, peptides and other complex analytes, with expertise in microsampling approaches and advanced LC-MS workflows designed for modern bioanalytical challenges. Known for its speed, reliability and audit readiness, Veloxity helps sponsors generate inspection-ready data quickly and move programs forward with confidence.
Learn more at www.veloxitylabs.com.
